Business Wire

Spectro Cloud Closes $75m Series C Led by Growth Equity at Goldman Sachs Alternatives

19.11.2024 13:00:00 CET | Business Wire | Press Release

Share

Spectro Cloud, a leader in modern multi-cluster Kubernetes management at scale across a variety of deployment environments, including on-premises hardware, single and multi-cloud, and the edge, today announced it has completed a $75 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives with participation from existing Spectro Cloud investors. The investment comes at a turning point of complexity in the IT industry, with the evolution from legacy, virtual machine (VM)-based applications to a containerized, cloud native ecosystem, with artificial intelligence (AI) driving an explosion of use at the edge.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241119538933/en/

Spectro Cloud closes $75m Series C funding round, led by Growth Equity at Goldman Sachs Alternatives. Learn more at spectrocloud.com. (Graphic: Business Wire)

Leading organizations across industries (including technology, manufacturing, retail, oil & gas, healthcare, telecommunications, defense and intelligence agencies) are relying on Spectro Cloud’s Palette software platform to help accelerate their Kubernetes adoption. By helping companies improve operating efficiency and more effectively run mission-critical application workloads, Spectro Cloud has achieved three consecutive years of triple-digit ARR growth.

“What IT leaders need today is a modern approach to comprehensive, full lifecycle management for Kubernetes at scale, one that is optimized to support the unique needs of data centers, clouds, and the edge,” said Tenry Fu, CEO and co-founder of Spectro Cloud. “We founded Spectro Cloud five years ago aiming to make Kubernetes easy to manage and consume in any environment, and this investment from Goldman Sachs is validation of the tremendous opportunity we have ahead of us.”

“In the past five years, Spectro Cloud has established itself as a leader in helping organizations realize the true potential of Kubernetes and cloud native technologies, making it more accessible and manageable at scale, across any environment,” said Michael Reilly, an Investor at Growth Equity at Goldman Sachs Alternatives who will be joining Spectro Cloud’s Board of Directors. “The incredible success Tenry and his team have achieved proves that enterprises are realizing the value. We are excited for the opportunity ahead in multi-cluster environments, especially bare metal deployments in data centers for VM and GPU management, and AI inference at the edge, which could drive tremendous growth.”

Spectro Cloud will use its Series C funding to accelerate product innovation, particularly in the uniquely complex area of edge computing, and to invest in continuing to offer award-winning customer experience and support, and scale new go-to-market partnerships and technology alliances.

To see Spectro Cloud’s Palette platform in action, book a demo at spectrocloud.com or visit booth #1396 at AWS re:Invent in Las Vegas, and booth #639 at Gartner IOCS in Las Vegas.

Read the announcement blog here.

About Spectro Cloud

Spectro Cloud uniquely enables organizations to deploy and manage Kubernetes in production, at scale. Its Palette enterprise Kubernetes management platform gives Platform Engineering, IT Operations and DevOps teams effortless control of the full Kubernetes lifecycle. With support for both VM and container workloads, Palette is a truly unified management platform across clouds, data centers, bare metal and edge environments. IT Operations teams are empowered to support their developers with curated Kubernetes stacks and tools based on their specific needs, with granular governance and enterprise-grade security. Spectro Cloud is a Gartner Cool Vendor, CRN Tech Innovator, and a ‘leader’ and ‘outperformer’ in GigaOm’s 2024 Radars for Edge Kubernetes and Managed Kubernetes.

Co-founded in 2019 by CEO Tenry Fu, Vice President of Engineering Gautam Joshi and Chief Technology Officer Saad Malik, Spectro Cloud is backed by Alter Venture Partners, Boldstart Ventures, Firebolt Ventures, Growth Equity at Goldman Sachs Alternatives, NEC and Translink Orchestrating Future Fund, Qualcomm Ventures, Sierra Ventures, Stripes, T-Mobile Ventures, TSG and WestWave Capital.

For more information, visit https://www.spectrocloud.com or follow @spectrocloudinc and @spectrocloudgov on X.

About Growth Equity at Goldman Sachs Alternatives

Goldman Sachs (NYSE: GS) is one of the leading investors in alternatives globally, with over $500 billion in assets and more than 30 years of experience. The business invests in the full spectrum of alternatives including private equity, growth equity, private credit, real estate, infrastructure, hedge funds and sustainability. Clients access these solutions through direct strategies, customized partnerships, and open-architecture programs. The business is driven by a focus on partnership and shared success with its clients, seeking to deliver long-term investment performance drawing on its global network and deep expertise across industries and markets. The alternative investments platform is part of Goldman Sachs Asset Management, which delivers investment and advisory services across public and private markets for the world’s leading institutions, financial advisors and individuals. Goldman Sachs has over $3.1 trillion in assets under supervision globally as of September 30, 2024. Since 2003, Growth Equity at Goldman Sachs Alternatives has invested over $13 billion in companies led by visionary founders and CEOs. The team focuses on investments in growth stage and technology-driven companies spanning multiple industries, including enterprise technology, financial technology, consumer and healthcare.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241119538933/en/

Contacts

PR contacts:
Spectro Cloud: Ant Newman – ant@spectrocloud.com

Goldman Sachs: Victoria Zarella – victoria.zarella@gs.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye